BACKGROUND: The aim of this study was to investigate the effects of Roux-en-Y gastric bypass (RYGB) on glucose tolerance and insulin resistance in type 2 diabetic rats and the possible mechanisms involved in this process. METHODS: Thirty Goto-Kakizaki (GK) rats were randomly divided into three groups: RYGB operation, sham operation, and food restriction groups. Ten Wistar rats were used as non-diabetic control. The body weight and food consumption of rats were recorded 1 week before or every week after surgery. The fasting blood sugar and oral glucose tolerance test were performed using blood glucose meter. The levels of plasma insulin or glucagon-like peptide-1 (GLP-1) were evaluated by enzyme-linked immunosorbent assay. The insulin resistance was quantified using homeostasis model assessment method. The expression of GLP-1 receptor, Bcl-2, Bax, and caspase-3 was determined by Western blotting. RESULTS: Our results revealed that RYGB efficiently improved both glucose tolerance and insulin resistance in GK diabetic rats by upregulating GLP-1/GLP-1R expression. In addition, GLP-1R agonist exendin-4 dose-dependently increased insulin secretion in RIN-m5F cells and regulated the proliferation and apoptosis of these cells. CONCLUSIONS: RYGB provides a valuable therapeutic option for patients with type 2 diabetes. GLP-1 may contribute to the regulation of pancreatic β-cell function through its receptor following RYGB.
BACKGROUND: The aim of this study was to investigate the effects of Roux-en-Y gastric bypass (RYGB) on glucose tolerance and insulin resistance in type 2 diabeticrats and the possible mechanisms involved in this process. METHODS: Thirty Goto-Kakizaki (GK) rats were randomly divided into three groups: RYGB operation, sham operation, and food restriction groups. Ten Wistar rats were used as non-diabetic control. The body weight and food consumption of rats were recorded 1 week before or every week after surgery. The fasting blood sugar and oral glucose tolerance test were performed using blood glucose meter. The levels of plasma insulin or glucagon-like peptide-1 (GLP-1) were evaluated by enzyme-linked immunosorbent assay. The insulin resistance was quantified using homeostasis model assessment method. The expression of GLP-1 receptor, Bcl-2, Bax, and caspase-3 was determined by Western blotting. RESULTS: Our results revealed that RYGB efficiently improved both glucose tolerance and insulin resistance in GK diabeticrats by upregulating GLP-1/GLP-1R expression. In addition, GLP-1R agonist exendin-4 dose-dependently increased insulin secretion in RIN-m5F cells and regulated the proliferation and apoptosis of these cells. CONCLUSIONS: RYGB provides a valuable therapeutic option for patients with type 2 diabetes. GLP-1 may contribute to the regulation of pancreatic β-cell function through its receptor following RYGB.
Authors: Francesco Rubino; Michel Gagner; Paolo Gentileschi; Subhash Kini; Shoji Fukuyama; John Feng; Ed Diamond Journal: Ann Surg Date: 2004-08 Impact factor: 12.969
Authors: Tammy L Kindel; Stephanie M Yoder; Randy J Seeley; David A D'Alessio; Patrick Tso Journal: J Gastrointest Surg Date: 2009-05-12 Impact factor: 3.452
Authors: Philip R Schauer; Bartolome Burguera; Sayeed Ikramuddin; Dan Cottam; William Gourash; Giselle Hamad; George M Eid; Samer Mattar; Ramesh Ramanathan; Emma Barinas-Mitchel; R Harsha Rao; Lewis Kuller; David Kelley Journal: Ann Surg Date: 2003-10 Impact factor: 12.969
Authors: I Marzo; C Brenner; N Zamzami; S A Susin; G Beutner; D Brdiczka; R Rémy; Z H Xie; J C Reed; G Kroemer Journal: J Exp Med Date: 1998-04-20 Impact factor: 14.307
Authors: Gil Faria; John Preto; Eduardo Lima da Costa; João Tiago Guimarães; Conceição Calhau; António Taveira-Gomes Journal: Obes Surg Date: 2013-01 Impact factor: 4.129
Authors: Hans Eickhoff; Teresa M Louro; Paulo N Matafome; Filipa Vasconcelos; Raquel M Seiça; Francisco Castro E Sousa Journal: Obes Surg Date: 2015-01 Impact factor: 4.129